Aktis Oncology, Inc. (AKTS) vs Janux Therapeutics, Inc. (JANX)
Aktis Oncology, Inc. and Janux Therapeutics, Inc. are both Biotechnology companies. Aktis Oncology, Inc. and Janux Therapeutics, Inc. are of similar size ($1.1B and $1.0B). Janux Therapeutics, Inc. has the higher net margin (−427.5% vs −782.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Janux Therapeutics, Inc. leads on 11 and Aktis Oncology, Inc. on 2.
Valuation
Profitability
| Metric | AKTS | JANX | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | (939.13%) | (598.15%) | 0.00% |
| Net margin | (781.95%) | (427.47%) | 0.00% |
| Free cash flow margin | (1,442.91%) | (174.69%) | 0.00% |
| Return on equity | (34.45%) | (10.70%) | (57.72%) |
| Return on assets | (27.09%) | (10.06%) | (49.22%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack